Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint

Reuters2026/07/30 20:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Karyopharm reported topline results from its Phase 3 XPORT-EC-042 maintenance trial of selinexor in advanced or recurrent endometrial cancer.
The study missed its main goal, though results showed a directional benefit for selinexor versus placebo.
Detailed findings have not been presented yet; management expects to disclose the full dataset at a future medical meeting.
Safety was consistent with prior experience, with no new issues flagged.
Karyopharm plans to scale back endometrial cancer investment, shifting focus to myelofibrosis and multiple myeloma programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607301605PR_NEWS_USPR_____NE16133) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint

You may also like

Crypto prices